These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 32238094

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs.
    Bharadwaj S, Azhar EI, Kamal MA, Bajrai LH, Dubey A, Jha K, Yadava U, Kang SG, Dwivedi VD.
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI, Shaikh M, Tul-Wahab A, Ur-Rahman A.
    PLoS One; 2020 Apr; 15(7):e0235030. PubMed ID: 32706783
    [Abstract] [Full Text] [Related]

  • 11. Finding potent inhibitors for COVID-19 main protease (Mpro): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA.
    Motiwale M, Yadav NS, Kumar S, Kushwaha T, Choudhir G, Sharma S, Singour PK.
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [Abstract] [Full Text] [Related]

  • 12. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ.
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.
    Arunkumar M, Gunaseelan S, Kubendran Aravind M, Mohankumar V, Anupam P, Harikrishnan M, Siva A, Ashokkumar B, Varalakshmi P.
    J Biomol Struct Dyn; 2022 Oct; 40(19):8961-8988. PubMed ID: 34014150
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R, Hadizadeh F, Abdizadeh T.
    J Biomol Struct Dyn; 2023 Oct; 41(13):5915-5945. PubMed ID: 35848354
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2.
    Al-Khafaji K, Al-Duhaidahawi D, Taskin Tok T.
    J Biomol Struct Dyn; 2021 Jun; 39(9):3387-3395. PubMed ID: 32364041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.